سعر اتكونافيل 50 مجم 12 قرص 2022

Avanafil 50 mg tablets (PDE5 inhibitor for erectile dysfunction), pack of 12 tablets (3 strips), Atco Pharma.

• Treatment of erectile dysfunction in adult men (sexual stimulation required).Population: Adult menEuropean Medicines Agency (EPAR product information)

• Common: headache, flushing, nasal congestion. Uncommon: dizziness, somnolence, sinus headache, blurred vision, palpitations, hot flush, sinus congestion, exertional dyspnoea, dyspepsia, nausea, vomiting, stomach discomfort, back pain, muscle tightness, fatigue, increased hepatic enzymes, abnormal ECG, increased heart rate. Rare events include influenza, nasopharyngitis, angina, tachycardia, hypertension, hypotension, epistaxis, rash and spontaneous penile erection. Priapism, NAION and sudden hearing loss have been reported with other PDE5 inhibitors (none in avanafil trials).International label, same formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to avanafil or any excipient; use of any organic nitrate or nitric oxide donor (e.g. amyl nitrite); co-administration with guanylate cyclase stimulators such as riociguat.International label, same formulation · European Medicines Agency (EPAR product information)
• Myocardial infarction, stroke or life-threatening arrhythmia within the last 6 months; resting hypotension (<90/50 mmHg) or hypertension (>170/100 mmHg); unstable angina, angina with sexual intercourse, or congestive heart failure NYHA class 2 or greater.International label, same formulation · European Medicines Agency (EPAR product information)
• Severe hepatic impairment (Child-Pugh C); severe renal impairment (CrCl <30 mL/min); loss of vision in one eye due to NAION; known hereditary degenerative retinal disorders; use of potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin).International label, same formulation · European Medicines Agency (EPAR product information)

• Assess cardiovascular status before treatment (cardiac risk of sexual activity); avanafil causes mild transient blood-pressure decreases; patients with left ventricular outflow obstruction may be sensitive to vasodilators.International label, same formulation · European Medicines Agency (EPAR product information)
• Priapism: seek immediate medical help for erections lasting 4 hours or more; use with caution with penile deformation or conditions predisposing to priapism (sickle cell anaemia, multiple myeloma, leukaemia).International label, same formulation · European Medicines Agency (EPAR product information)
• Sudden visual defects (including NAION and central serous chorioretinopathy) or sudden decrease/loss of hearing: stop treatment and seek medical attention promptly.International label, same formulation · European Medicines Agency (EPAR product information)

• Organic nitrates / nitric oxide donors (e.g. amyl nitrite)Augmented hypotensive effect; contraindicated. If a nitrate is medically necessary in a life-threatening situation within 12 hours of avanafil, give only under close medical supervision with haemodynamic monitoring.European Medicines Agency (EPAR product information)
• Riociguat (guanylate cyclase stimulators)Additive hypotension; contraindicated.European Medicines Agency (EPAR product information)
• Potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, itraconazole, clarithromycin)Large increases in avanafil exposure (ketoconazole AUC 14-fold, ritonavir 13-fold); contraindicated.European Medicines Agency (EPAR product information)

• Not indicated for use in women; no data in pregnant women; animal studies do not indicate harmful effects.International label, same formulation · European Medicines Agency (EPAR product information)
• No data on use during breastfeeding (not indicated for women).International label, same formulation · European Medicines Agency (EPAR product information)

• Avanafil: Highly selective, reversible inhibitor of cGMP-specific phosphodiesterase type 5; when sexual stimulation releases nitric oxide, PDE5 inhibition raises cGMP in the corpus cavernosum, causing smooth-muscle relaxation and erection; no effect without sexual stimulation (EU SmPC).